EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

A pragmatic monitoring model for risk of non‐relapse mortality based on biomarkers in patients undergoing allogeneic haematopoietic stem‐cell transplantation

Yangliu Shao, Jingjing Yang, Xiaobo Li iD, Yuqi He, Di Guan, Ri Xu, Lili Miao, Jianyun Wen, Xiaoqin Feng, Tong Wu, Fan Yang, Zeliang Song und 8 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.70070 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Yangliu Shao und 19 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Beijing Nova Program Cross-Cutting Project, Capital's Funds for Health Improvement and Research, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biomarkers predict non‐relapse mortality (NRM) primarily driven by acute graft‐versus‐host disease (aGVHD) after allogeneic haematopoietic stem cell transplantation (allo‐HSCT), yet existing single time point models lack clinical adaptability. In a prospective observational multicentre Chinese cohort of 619 allo‐HSCT patients, serum concentrations of suppressor of tumorigenesis 2 (ST2), regenerating islet‐derived 3α, tumour necrosis factor receptor 1 (TNFR1), interleukin‐6 and interleukin‐8 were measured at multiple time points during the first 3 months post‐transplantation. Cohorts were divided into modelling ( n = 460, training/test) and validation ( n = 159) sets. A model based on the approximately maximum concentrations of ST2 and TNFR1 reached area under the curve of 0.85 and 0.95 in the test and validation cohorts, respectively, which was the highest among the models based on other biomarker panels. The model stratified validation cohort patients into high‐risk (47.37%), moderate‐risk (9.76%) and low‐risk (0.0%) groups with significantly different 6‐month NRM ( p < 0.001). Using a universal threshold, the model consistently stratified patients into moderate–high‐risk versus low‐risk groups for NRM at all time points (days 7, 14, 28, aGVHD onset). Cumulative 6‐month NRM was significantly higher in moderate–high‐risk groups (20.00%, 33.33%, 37.50%, 30.77%) versus low‐risk groups (5.22%, 5.22%, 3.88%, 7.14%). The application of this model is not confined to specific time points or clinical characteristics, rendering it a flexible and pragmatic tool in a clinical setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationHumansMaleFemaleBiomarkersAdultMiddle AgedGraft vs Host DiseaseProspective StudiesTransplantation, HomologousAdolescentInterleukin-1 Receptor-Like 1 ProteinYoung AdultReceptors, Tumor Necrosis Factor, Type IAged

Stichwörter der Autor:innen

acute graft‐versus‐host diseasebiomarkerhaematopoietic stem cell transplantationnon‐relapse mortality

Substanzen

BiomarkersInterleukin-1 Receptor-Like 1 ProteinReceptors, Tumor Necrosis Factor, Type IIL1RL1 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
  • Medical School of Chinese PLA, Beijing, China.
  • Beijing BFR Gene Diagnostics LTD, Beijing, China.
  • Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Department of Bone Marrow Transplantation, Beijing GoBroad Boren Hospital, Beijing, China.
  • Department of Pediatric Hematology, Children's Hospital, Capital Institute of Pediatrics, Beijing, China.

ORCID-Profile: Xiaobo Li, Rong Liu, Dao Wang, Liping Dou, Daihong Liu

Förderung

  • Beijing Nova Program Cross-Cutting Project
  • Capital's Funds for Health Improvement and Research
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Beijing Natural Science Foundation of China

Zitieren

APA

Shao, Y., Yang, J., Li, X., He, Y., Guan, D., Xu, R., Miao, L., Wen, J., Feng, X., Wu, T., Yang, F., Song, Z., Liu, R., Wang, D., Wei, Z., Wang, J., Liu, X., He, Y., Dou, L., & Liu, D. (2025). A pragmatic monitoring model for risk of non‐relapse mortality based on biomarkers in patients undergoing allogeneic haematopoietic stem‐cell transplantation. British Journal of Haematology. https://doi.org/10.1111/bjh.70070

Vancouver

Shao Y, Yang J, Li X, He Y, Guan D, Xu R, et al. A pragmatic monitoring model for risk of non‐relapse mortality based on biomarkers in patients undergoing allogeneic haematopoietic stem‐cell transplantation. British Journal of Haematology. 2025. doi:10.1111/bjh.70070

BibTeX
@article{Shao2025,
  author = {Shao, Yangliu and Yang, Jingjing and Li, Xiaobo and He, Yuqi and Guan, Di and Xu, Ri and Miao, Lili and Wen, Jianyun and Feng, Xiaoqin and Wu, Tong and Yang, Fan and Song, Zeliang and Liu, Rong and Wang, Dao and Wei, Zhijie and Wang, Jingbo and Liu, Xiangjun and He, Yuelin and Dou, Liping and Liu, Daihong},
  title = {A pragmatic monitoring model for risk of non‐relapse mortality based on biomarkers in patients undergoing allogeneic haematopoietic stem‐cell transplantation},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.70070}
}
Kostenlos starten →